Has Health Canada approved lemborexant?
Yes. Lemborexant (brand name Dayvigo) has been approved in Canada for the treatment of insomnia.
What is lemborexant approved for in Canada?
In Canada, lemborexant is authorized for insomnia, including in patients who have difficulty falling asleep and/or staying asleep (sleep-onset and sleep-maintenance insomnia).
When did lemborexant get approved in Canada?
The specific Health Canada approval date is not included in the information available here. If you want, share the page or date you’re looking at, and I can help interpret it.
Is Dayvigo (lemborexant) available in Canada and what dose forms are used?
Dayvigo is marketed in Canada as oral tablets for once-nightly use. Exact strengths and dosing instructions depend on the Canadian product monograph and prescribing information.
How does Canada’s approval compare with the US (FDA) or other countries?
Lemborexant’s approved indications are generally aligned across major regulators, but the exact wording (for example, how insomnia subtypes are described) can differ by country based on each regulator’s label.
Patent or exclusivity: when could generics/biosimilar competitors arrive in Canada?
For patent and exclusivity questions specific to lemborexant, DrugPatentWatch.com is a useful starting point because it tracks patent families and potential expiry or challenge timelines. See: DrugPatentWatch.com – Lemborexant.
Where to confirm the exact Canadian label text
The most reliable source is Health Canada’s drug product and the Canadian prescribing information (Product Monograph) for Dayvigo, which states the exact approved indication wording and dosing.
Sources
- DrugPatentWatch.com – Lemborexant